

## LISTING OF CLAIMS

1. (currently amended) An agent for treating or preventing a cerebrovascular disorder, wherein the agent comprises ~~an HGF gene~~ a nucleic acid encoding a protein effective as a hepatocyte growth factor.
2. (original) The agent of claim 1, wherein the cerebrovascular disorder is a cerebral infarction.
3. (currently amended) The agent of ~~claim 1 or 2~~ claim 1, wherein the agent is in the form of a tablet, pill, sugar-coated tablet, capsule, liquid, gel, ointment, syrup, slurry, or suspension.
4. (currently amended) The agent of ~~any one of claims 1 to 3~~ claim 1, wherein the agent is used ~~to transfer a gene into a cell by a method employing~~ further comprises a viral envelope vector, ~~an~~ internal type liposome, ~~an~~ electrostatic type liposome, ~~an~~ HVJ-liposome or improved HVJ-liposome, ~~a receptor-mediated gene transfer method, a method for transferring a nucleic acid molecule along with a carrier into a cell by using a particle gun, a direct introduction method using a naked DNA, or an introduction method using~~ a cationic polymer, or combinations of two or more thereof.
5. (currently amended) The agent of ~~any one of claims 1 to 3~~ claim 1, wherein the agent is used ~~to transfer a gene into a cell by employing~~ further comprises an HVJ-envelope.
6. (currently amended) A method for treating or preventing a cerebrovascular disorder, wherein the method comprises ~~the step of introducing an HGF gene into a mammal~~ introduction of the agent of claim 1.
7. (original) The method of claim 6, wherein the cerebrovascular disorder is a cerebral infarction.

8. (currently amended) The method of ~~claim 6 or 7~~ claim 6, wherein the ~~method~~ introduction of the nucleic acid comprises ~~the step of introducing an HGF gene into a mammal two to three times by employing the nucleic acid by an HVJ-envelope.~~

9. (cancelled)

10. (cancelled)

11. (new) The method of claim 6, wherein the introduction of the nucleic acid comprises introducing the nucleic acid by viral envelope vectors, internal type liposomes, electrostatic type liposomes, HVJ-liposomes or improved HVJ-liposomes, receptor-mediated gene transfer, transfer of nucleic acid into a cell using a particle gun (gene gun), direct introduction of naked-nucleic acid, introduction using a cationic polymer, or combinations of two or more thereof.